SG10201504917PA - Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity - Google Patents
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced ToxicityInfo
- Publication number
- SG10201504917PA SG10201504917PA SG10201504917PA SG10201504917PA SG10201504917PA SG 10201504917P A SG10201504917P A SG 10201504917PA SG 10201504917P A SG10201504917P A SG 10201504917PA SG 10201504917P A SG10201504917P A SG 10201504917PA SG 10201504917P A SG10201504917P A SG 10201504917PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- monoclonal antibodies
- autoimmune disorders
- reduced toxicity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69851705P | 2005-07-11 | 2005-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201504917PA true SG10201504917PA (en) | 2015-07-30 |
Family
ID=37637980
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201504917PA SG10201504917PA (en) | 2005-07-11 | 2006-07-11 | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
SG2011097946A SG177944A1 (en) | 2005-07-11 | 2006-07-11 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
SG201005116-7A SG163615A1 (en) | 2005-07-11 | 2006-07-11 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011097946A SG177944A1 (en) | 2005-07-11 | 2006-07-11 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
SG201005116-7A SG163615A1 (en) | 2005-07-11 | 2006-07-11 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
Country Status (8)
Country | Link |
---|---|
US (1) | US8663634B2 (en) |
EP (2) | EP1904105A4 (en) |
JP (2) | JP2009500457A (en) |
AU (1) | AU2006267090B2 (en) |
CA (1) | CA2614640A1 (en) |
IL (1) | IL188592A (en) |
SG (3) | SG10201504917PA (en) |
WO (1) | WO2007009064A2 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
KR20080042905A (en) * | 2005-09-12 | 2008-05-15 | 노비뮨 에스 에이 | Anti-cd3 antibody formulations |
NZ573132A (en) * | 2006-06-06 | 2012-05-25 | Glaxo Group Ltd | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
WO2007147090A2 (en) * | 2006-06-14 | 2007-12-21 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
AU2007337082A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics Inc. | Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
WO2009117030A2 (en) * | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
HUE028962T2 (en) * | 2008-03-13 | 2017-01-30 | Biotest Ag | Agent for treating disease |
AU2009224690B2 (en) * | 2008-03-13 | 2014-10-09 | Biotest Ag | Agent for treating disease |
CA2718184A1 (en) * | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
KR101614494B1 (en) | 2008-04-02 | 2016-04-22 | 마크로제닉스, 인크. | Bcr-complex-specific antibodies and methods of using same |
JP5555223B2 (en) | 2008-04-02 | 2014-07-23 | マクロジェニクス,インコーポレーテッド | HER2 / neu specific antibody and method of use thereof |
US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
ES2528419T3 (en) * | 2008-09-29 | 2015-02-09 | Biotest Ag | Composition for the treatment of diseases |
WO2011047172A1 (en) * | 2009-10-14 | 2011-04-21 | Celtaxsys, Inc. | Method of treating inflammation |
WO2011050106A2 (en) * | 2009-10-20 | 2011-04-28 | Tolerx, Inc. | Anti-cd3 antibody dosing in autoimmune disease |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
EP2525822B1 (en) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
WO2011091177A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
AU2011223782B2 (en) | 2010-03-04 | 2014-09-18 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US20130115207A1 (en) * | 2010-04-09 | 2013-05-09 | The General Hospital Corporation | Methods for the treatment of autoimmune diseases |
US20130095121A1 (en) * | 2010-06-25 | 2013-04-18 | Aoife Brennan | Methods of treating patients with immune-related diseases |
WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
CN103842383B (en) * | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | Polyspecific FAB fusion proteins and its application method |
BR122016016837A2 (en) | 2011-05-21 | 2019-08-27 | Macrogenics Inc | cd3 binding molecules; cd3 binding antibodies; pharmaceutical compositions; and uses of the cd3 binding molecule |
JP2015091761A (en) * | 2012-02-23 | 2015-05-14 | 国立大学法人大阪大学 | Composition for treating central nervous injury and use thereof |
EP2850106B1 (en) * | 2012-05-18 | 2022-03-23 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
EP2892924B1 (en) | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
EP2895203A4 (en) * | 2012-06-15 | 2016-09-28 | Imaginab Inc | Antigen binding constructs to cd3 |
US9511110B2 (en) * | 2012-09-27 | 2016-12-06 | Perle Bioscience, Inc. | Generation of new pancreatic beta cells |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
KR102459720B1 (en) * | 2014-04-08 | 2022-10-26 | 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. | Combination therapy for the treatment of autoimmune diseases |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
TW201709929A (en) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | Combination therapy for the treatment of cancer |
WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
TWI781098B (en) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
EP3515491A4 (en) | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | Cd123 binding proteins and related compositions and methods |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
EP3984554A4 (en) * | 2019-06-11 | 2023-11-08 | ONO Pharmaceutical Co., Ltd. | Immunosuppression agent |
WO2021195544A1 (en) * | 2020-03-27 | 2021-09-30 | Platelet Biogenesis, Inc. | Novel anucleated cells for the treatment of diseases |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51133489A (en) | 1975-05-14 | 1976-11-19 | Tokyo Daigaku | Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities |
US4658019A (en) | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4221794A (en) | 1979-06-21 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | Method of imparting immunomodulating and antiviral activity |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
NZ214503A (en) | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
US5078998A (en) | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
US4882424A (en) | 1987-05-11 | 1989-11-21 | Dana-Farber Cancer Institute, Inc. | Activation antigen |
IL92382A (en) | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
WO1993019767A1 (en) | 1992-04-07 | 1993-10-14 | The Regents Of The University Of Michigan | Cd28 pathway immunoregulation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69018990T2 (en) | 1989-07-14 | 1995-12-14 | Praxis Biolog Inc | STABLE INTERLEUKINE VACCINE COMPOSITIONS CONTAINING. |
SE8903100D0 (en) | 1989-09-20 | 1989-09-20 | Pharmacia Ab | NEW PHARMACEUTICAL AGENT |
DE69032484T4 (en) | 1989-10-27 | 1999-09-16 | Arch Dev Corp | COMPOSITIONS AND THE USE THEREOF TO PROMOTE IMMUNOPOTENTIATION |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ZA91463B (en) | 1990-01-25 | 1992-09-30 | Bristol Myers Squibb Co | Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody |
EP0537293A4 (en) | 1990-07-02 | 1993-09-08 | Bristol-Myers Company | Ligand for cd28 receptor on b cells and methods |
JPH06505396A (en) | 1991-03-08 | 1994-06-23 | サイトメッド,インコーポレイテッド | Soluble CD28 protein and therapeutic methods using the same |
CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
AU4535893A (en) | 1992-06-15 | 1994-01-04 | Regents Of The University Of California, The | Screening assay for the identification of immunosuppressive drugs |
WO1994023760A1 (en) | 1993-04-14 | 1994-10-27 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
EP0711345A1 (en) | 1993-07-26 | 1996-05-15 | Dana Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
AU7467898A (en) * | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
US7041289B1 (en) | 1997-12-05 | 2006-05-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for treating established spontaneous auto-immune diseases in mammals |
JP2003531816A (en) | 1999-10-01 | 2003-10-28 | バイオトランスプラント,インコーポレイテッド | Methods for inducing functional tolerance in transgenic products |
GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
US20030216551A1 (en) | 2002-03-08 | 2003-11-20 | Diabetogen Biosciences Inc. | Fully human anti-CD3 monoclonal antibodies |
HUE025101T2 (en) * | 2002-04-26 | 2016-02-29 | Genentech Inc | Non-affinity purification of proteins |
AU2003232171A1 (en) | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a beta cell resting compound |
AU2003232172A1 (en) | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a glp-1 compound |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7883703B2 (en) | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
CA2554978A1 (en) * | 2004-02-04 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity |
US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
US8663634B2 (en) * | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
NZ573132A (en) | 2006-06-06 | 2012-05-25 | Glaxo Group Ltd | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
AU2007337082A1 (en) | 2006-12-21 | 2008-07-03 | Macrogenics Inc. | Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
-
2006
- 2006-07-11 US US11/485,557 patent/US8663634B2/en active Active
- 2006-07-11 CA CA002614640A patent/CA2614640A1/en not_active Abandoned
- 2006-07-11 JP JP2008521639A patent/JP2009500457A/en active Pending
- 2006-07-11 SG SG10201504917PA patent/SG10201504917PA/en unknown
- 2006-07-11 EP EP06787311A patent/EP1904105A4/en not_active Ceased
- 2006-07-11 SG SG2011097946A patent/SG177944A1/en unknown
- 2006-07-11 SG SG201005116-7A patent/SG163615A1/en unknown
- 2006-07-11 EP EP12166907A patent/EP2497496A3/en not_active Withdrawn
- 2006-07-11 WO PCT/US2006/027386 patent/WO2007009064A2/en active Application Filing
- 2006-07-11 AU AU2006267090A patent/AU2006267090B2/en active Active
-
2008
- 2008-01-03 IL IL188592A patent/IL188592A/en active IP Right Grant
-
2012
- 2012-07-10 JP JP2012154666A patent/JP2013005798A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013005798A (en) | 2013-01-10 |
IL188592A (en) | 2013-08-29 |
EP2497496A3 (en) | 2013-02-20 |
US20070077246A1 (en) | 2007-04-05 |
SG163615A1 (en) | 2010-08-30 |
AU2006267090A1 (en) | 2007-01-18 |
IL188592A0 (en) | 2008-04-13 |
JP2009500457A (en) | 2009-01-08 |
WO2007009064A2 (en) | 2007-01-18 |
EP1904105A4 (en) | 2010-02-17 |
CA2614640A1 (en) | 2007-01-18 |
SG177944A1 (en) | 2012-02-28 |
WO2007009064A3 (en) | 2009-04-23 |
EP1904105A2 (en) | 2008-04-02 |
US8663634B2 (en) | 2014-03-04 |
AU2006267090B2 (en) | 2013-03-07 |
EP2497496A2 (en) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201504917PA (en) | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity | |
SG10201504662WA (en) | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity | |
IL272883A (en) | Monoclonal antibodies and uses thereof | |
HRP20181565T1 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
HK1252316A1 (en) | Use of anti il-1beta antibodies | |
IL199887A0 (en) | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity | |
IL188591A0 (en) | Methods of treating autoimmune disease using humanized anti-cd16a antibodies | |
IL179672A0 (en) | Anti-cd3 antibodies | |
IL206709A0 (en) | Il-31 monoclonal antibodies | |
EP1904101A4 (en) | Anti-cd19 antibody therapy for the transplantation | |
SG10201404801YA (en) | Monoclonal antibody | |
EP1853313A4 (en) | Humanized l243 antibodies | |
EP1761566A4 (en) | Humanized anti-tag-72 monoclonal antibodies | |
IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
IL191217A (en) | Humanized monoclonal anti-il-17 antibodies | |
IL178409A0 (en) | Humanized anti-tgf-beta antibodies | |
PT2343320T (en) | Anti-gitr antibodies and uses thereof | |
EP1915177A4 (en) | Alpha-synuclein antibodies and methods related thereto | |
PL1765396T3 (en) | Anti-psgl-1 antibodies | |
EP1869192A4 (en) | Framework-shuffling of antibodies | |
HK1119179A1 (en) | Methods for the selection of aptamers | |
EP1718749A4 (en) | Humanized antibody | |
IL243687A0 (en) | Anti-cs1 antibodies for the treatment of multiple myeloma | |
EP1712564A4 (en) | Anti-nc1 monoclonal antibody | |
GB0415644D0 (en) | Monoclonal antibody |